In vitro pharmacological characterization of (± )-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a nicotinic acetylcholine receptor ligand

Brain Research

Volumn 981, Issue 1-2, 2003, Pages 85-98

  Rao, Tadimeti S ^a   Adams, Pamala B ^a   Correa, Lucia D ^a   Santori, Emily M ^a   Sacaan, Aida I ^a,b   Reid, Richard T ^a,c   Suto, Carla M ^a   Vernier, Jean Michel ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Arizeke Pharmaceuticals Inc   (United States)

^c Banck Clinical Research Center   (United States)

Author keywords

Nicotinic acetylcholine receptor; SIB 1553A

Indexed keywords

4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; ACETYLCHOLINE; DICHOLINE SUBERATE; EPIBATIDINE; HISTAMINE RECEPTOR; LIGAND; MECAMYLAMINE; N METHYL DEXTRO ASPARTIC ACID; NICOTINE; NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND; NICOTINIC RECEPTOR; NORADRENALIN; RECEPTOR SUBUNIT; RECOMBINANT RECEPTOR; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCIUM; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DOPAMINE UPTAKE INHIBITOR; N METHYLASPARTIC ACID; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; NOMIFENSINE; PHENOL DERIVATIVE; PHYSOSTIGMINE; PROTEIN SUBUNIT; PYRROLIDINE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CALCIUM TRANSPORT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; OLFACTORY BULB; PHARMACODYNAMICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; ANIMAL; ATTENTION; BLOOD; BRAIN; CELL LINE; COGNITION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; EMBRYO; EXTRACELLULAR SPACE; HISTOLOGY; HUMAN; IN VITRO STUDY; METABOLISM; METHODOLOGY; RADIOASSAY; SPRAGUE DAWLEY RAT;

ANIMALS; ATTENTION; BRAIN; CALCIUM; CELL LINE; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; COGNITION; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO; EXTRACELLULAR SPACE; HUMANS; LIGANDS; MALE; N-METHYLASPARTATE; NEUROTRANSMITTER AGENTS; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; NOMIFENSINE; PHENOLS; PHYSOSTIGMINE; PROTEIN SUBUNITS; PYRROLIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; RECOMBINANT PROTEINS;

EID: 0141686999     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02979-2     Document Type: Article

References (36)

1. 3H]GBR12935 binding in vitro to rat striatal membranes: Labeling of dopamine uptake complex. J. Neurochem. 48:1987;1887-1896.
2. Arneric S.P., Brioni J.D. Neuronal Nicotinic Receptors. 1999;Wiley-Liss, New York.
3. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
4. Bontempi B., Whelan K.T., Risbrough V.B., Rao T.S., Buccafusco J.J., Llloyd G.K., Menzaghi F. SIB-1553A, ((± )-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride, a subtype selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and non human primates. J. Pharmacol. Exp. Ther. 299:2001;297-306.
5. Buccafusco J.J., Jackson W.J. Beneficial effects of nicotine administered prior to delayed matching to sample task in the young and aged monkeys. Neurobiol. Aging. 12:1996;233-238.
6. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.E., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors hα2β2, hα2β4, hα3β2, hα4β2, hα4β4 and hα7 expressed in xenopus oocytes. J. Pharmacol. Exp. Ther. 280:1997;346-356.
7. Chavez-Noriega L.E., Gillespie A., Stauderman K.A., Crona J.H., Claeps B.O., Elliott K.J., Reid R.T., Rao T.S., Velicelebi G., Harpold M.H., Johnson E.C., Corey-Naeve J. Characterization of the recombinant human neuronal nicotinic acetylcholine receptors a3b2 and a4b2 stably expressed in HEK 293 cells. Neuropharmacology. 39:2000;2453-2560.
8. 3H]dopamine release. Br. J. Pharmacol. 117:1996;595-606.
9. 125I]α-bungarotoxin receptor subtype. Mol. Pharmacol. 47:1995;164-171.
10. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Keller K.J. A subtype of nicotinic cholinergic receptor is composed of α4β2 subunits and upregulated by chronic nicotine treatment. Mol. Pharmacol. 41:1992;31-37.
11. Gurley D.A., Lanthorn T.H., Ryan T., Lujowskyj S., Gordon J. Comparison of nicotine and the alpha-7-selective agonist AR-R 17779 on nAChRs expressed in xenopus oocytes. Soc. Neurosci. Abstr. 24:1998;331.10.
12. Harvey S.C., Leutje C.W. Determinants of competitive antagonist effects of nicotine on neuronal nicotinic receptor β subunits. J. Neurosci. 16:1996;3798-3806.
13. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology. 108:1992;417-431.
14. Lippiello P.M., Bencherif M., Gray J.A., Peters S., Grigoryan G., Hodeges H., Collins A.C. RJR-1403, a nicotinic agonist with CNS selectivity II. In vivo characterization. J. Pharmacol. Exp. Ther. 279:1996;1422-1429.
15. Maggio R., Riva M., Vaglani F., Fornai F., Racagni G., Corsini G.U. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J. Neural Transm. 104:1997;1113-1123.
16. Matecka D., Rothman R.B., Radesca L., deCosta B.R., Dersch C.M., Partilla J.S., Pert A., Glowa J.R., Wojnicki F.H.E., Rice K.C. Development of novel, potent, and selective dopamine re-uptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl] and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl[-4-(3-pheylpropyl)piperazines (GBR-12935 and GBR-12909). J. Med. Chem. 39:1996;4704-4716.
17. McAllister R.M., MeInyk J., Finkelstein J.Z., Adams E.C., Gardner G.B. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer. 24:1969;520-526.
18. Newhouse P., Sunderland T., Tariot P. Intravenous nicotine in AD. Psychopharmacology. 95:1988;171-175.
19. Newhouse P.A., Potter A., Lewin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases: implications for therapeutics. Drugs Aging. 11:1997;206-228.
20. Picciotto M.R., Zoli M., Lena C., Besis A., Lallemand Y., Le Noverre N., Vincent P., Pich E.M., Brulet P., Changeux J.-P. Abnormal avoidance learning in mice lacking functional high affinity nicotine receptor in the brain. Nature. 374:1995;65-67.
21. Picciotto M.R., Zoli M., Rimodini R., Lena C., Marubio L., Pich E.M., Fuxe K., Changeux J.-P. β2-Subunit-containing acetylcholine receptors are involved in the reinforcing properties of nicotine. Nature. 391:1998;173-176.
22. Rao T.S., Correa L.D., Lloyd G.K. Effects of lobeline and dimethylphenylpiperazinium iodide (DMPP) on N-methyl-D-aspartate (NMDA)-evoked acetylcholine release in vitro. Evidence for a lack of involvement of classical neuronal nicotinic acetylcholine receptors. Neuropharmacology. 36:1997;39-50.
23. Rao T.S., Correa L.D., Reid R.T., Lloyd G.K. Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (NAChR) ligands in the rat tail-flick assay. Neuropharmacology. 35:1996;393-405.
24. Reid R.T., Saccan A.I., Adams P.B., Correa L.D., Santori E.M., McDonald I.A., Lloyd G.K., Rao T.S. Pharmacological characterization of SIB-1553A, a novel subtype selective neuronal nicotinic acetylcholine receptor agonist. Soc. Neurosci. Abstr. 23:1997;477.17.
25. Role L., Berg D.K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 16:1996;1077-1085.
26. Sacaan A.I., Dunlop J.L., Lloyd G.K. Pharmacological characterization of neuronal acetylcholine-gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J. Pharmacol. Exp. Ther. 274:1995;224-230.
27. Sacaan A.I., Reid R.T., Santori E.M., Adams P.A., Correa L.D., Mahaffy L.S., Bleicher L., Cosford N.D.P., McDonald I.A., Rao T.S., Lloyd G.K. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist. J. Pharmacol. Exp. Ther. 280:1997;373-383.
28. Stauderman K., Mahaffy L.S., Akong M., Velicelebi G., Chavez-Noriega L.E., Crona J.H., Johnson E.C., Elliott K.J., Gillespie A., Reid R.T., Adams P.B., Harpold M.M., Corey-Naeve J. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations α2β4, α3β4 and α4β4 stably expressed in HEK cells. J. Pharmacol. Exp. Ther. 284:1998;777-789.
29. Tani Y., Saito K., Imoto M., Ohno T. Pharmacological characterization of nicotinic receptor mediated acetylcholine release in the rat brain: an in vivo microdialysis study. Eur. J. Pharmacol. 351:1998;181-188.
30. Terry A.V. Jr., Risbrough V.B., Buccafusco J.J., Menzaghi F. Effects of ((±)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol Hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J. Pharmacol. Exp. Ther. 301:2002;284-292.
31. Velicelebi G., Stauderman K.A., Varney M.A., Akong M., Hess S.D., Johnson E.C. Fluorescence techniques for measuring ion channel activity. Methods Enzymol. 293:1999;20-47.
32. Vernier J.-M., Abdellaoui H., Holsenback H., Cosford N.D.P., Bleicher L., Barker G., Bontempi B., Chavez Noriega L.E., Mengazhi F.M., Rao T.S., Reid R.T., Sacaan A.I., Suto C., Washburn M., Lloyd G.K., McDonald I.A. 4[2-(Methyl2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): A novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. Bio-org. J. Med. Chem. 42:1999;1684-1686.
33. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., Rice K.C. Sigma receptors: biology and function. Pharmacol. Rev. 42:1990;355-402.
34. Washburn M.S., Chavez-Noriega L.E., Crona J.H., Vernier J.-M., Johnson E.C. Electrophysiological characterization of SIB-1553A activity on recombinant human nicotinic receptors expressed in Xenopus oocytes. Soc. Neurosci. Abstr. 23:1997;1198.
35. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20:1997;92-98.
36. Zoli M., Lena C., Picciotto M.R., Changeux J.-P. Identification of four classes of brain nicotinic receptors using β2 mutant mice. J. Neurosci. 18:1998;4461-4472.